Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia

Ai Kuwahara; Ryu Sasaki; Masanori Fukushima; Masafumi Haraguchi; Satoshi Miuma; Hisamitsu Miyaaki; Kazuhiko Nakao

doi:10.1002/jgh3.12351

Shunt occlusion prior to lenvatinib administration prevents hepatic encephalopathy and hyperammonemia

JGH Open. 2020 May 8;4(4):775-776. doi: 10.1002/jgh3.12351. eCollection 2020 Aug.

Authors

Ai Kuwahara¹, Ryu Sasaki¹, Masanori Fukushima¹, Masafumi Haraguchi¹, Satoshi Miuma¹, Hisamitsu Miyaaki¹, Kazuhiko Nakao¹

Affiliation

¹ Department of Gastroenterology and Hepatology Nagasaki University Graduate School of Biomedical Sciences Nagasaki Japan.

Abstract

Shunt occlusion prior to lenvatinib administration prevented hyperammonemia and hepatic encephalopathy. Shunt occlusion may be an effective treatment option to administer molecular target agents in patients with portosystemic shunts.

Keywords: encephalopathy; lenvatinib; portosystemic shunt.